U.S. FDA prosecutors conducted an unannounced inspection of our company.

On January 12, 2015, without prior notice, Ms. Susan and one other FDA inspector from the U.S. Food and Drug Administration conducted a two-day unannounced, walk-in inspection of our company’s crude heparin sodium production facility. Thanks to our company’s well-established quality control procedures and the enthusiastic and confident attitude of our management team during the inspection, the inspectors were deeply impressed by our company’s comprehensive crude heparin quality system and advanced hardware facilities, and they delivered a highly positive and favorable assessment. At the conclusion of the inspection, Ms. Susan warmly invited our management team to take a commemorative photo together.